Institute of Metabolic Disorders
The Institute of Metabolic Disorders (IMD) focuses on drug discovery for the treatment of lipid-dependent fatty liver disease (NAFLD/NASH). The Institute aims to become a respected leader in metabolic disease treatment, striving to improve the quality of life for individuals with metabolic pathologies related to liver function loss.
Industries
Nr. of Employees
small (1-50)
Institute of Metabolic Disorders
Hampton, New Jersey, United States, North America
Products
Method for enhancing miR-185 expression to reduce LDL/cholesterol accumulation (patent)
A patented method that modulates microRNA expression to reduce low-density lipoprotein and cholesterol accumulation in cells.
Method for enhancing miR-185 expression to reduce LDL/cholesterol accumulation (patent)
A patented method that modulates microRNA expression to reduce low-density lipoprotein and cholesterol accumulation in cells.
Services
Preclinical research in metabolic liver disease
Research activities focused on discovery and preclinical evaluation of interventions for lipid-dependent liver disease and metabolic syndrome using in vivo and in vitro models.
Target discovery and validation
Identification and experimental validation of molecular targets in lipid metabolism and related pathways using genetic and biochemical approaches.
Development of genetically modified animal models
Generation and characterization of transgenic and humanized mouse models for studying metabolic dysfunction-associated steatohepatitis and related phenotypes.
Preclinical research in metabolic liver disease
Research activities focused on discovery and preclinical evaluation of interventions for lipid-dependent liver disease and metabolic syndrome using in vivo and in vitro models.
Target discovery and validation
Identification and experimental validation of molecular targets in lipid metabolism and related pathways using genetic and biochemical approaches.
Development of genetically modified animal models
Generation and characterization of transgenic and humanized mouse models for studying metabolic dysfunction-associated steatohepatitis and related phenotypes.
Expertise Areas
- Drug discovery for NAFLD/NASH
- Metabolic disease research
- Preclinical in vivo modeling
- Model organism genetics (yeast)
Key Technologies
- Genetically modified mouse models
- Yeast model systems (Saccharomyces cerevisiae)
- miRNA modulation
- Gene expression and protein interaction analysis